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The rapid development of genomic sequencing technologies has decreased 
the cost of genetic analysis to the extent that it seems plausible that genome-
scale sequencing could have widespread availability in pediatric care. 
Genomic sequencing provides a powerful diagnostic modality for patients 
who manifest symptoms of monogenic disease and an opportunity to detect 
health conditions before their development. However, many technical, 
clinical, ethical, and societal challenges should be addressed before such 
technology is widely deployed in pediatric practice. This article provides 
an overview of the Newborn Sequencing in Genomic Medicine and Public 
Health Consortium, which is investigating the application of genome-scale 
sequencing in newborns for both diagnosis and screening.
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Universal newborn screening (NBS) 
is an extraordinarily successful 
public health program, preventing 
morbidity and mortality through 
early diagnosis and management of 
conditions including rare inborn errors 
of metabolism. 1 Conditions such as 
phenylketonuria are not clinically 
evident at birth but lead to significant 
irreversible harm or death if not 
treated promptly. 2 NBS has saved 
countless lives and vastly improved the 
quality of children’s lives by allowing 
timely therapeutic interventions, and 
technological advances such as the use 
of tandem mass spectrometry 
(MS/MS) have played a significant 
role in expansion of NBS. 3,  4
The ability to analyze many or all 
genes in the genome simultaneously 
provides new opportunities for 
genomic medicine. The capacity of 
genome-scale sequencing for disease 
gene discovery is well documented, 5 
and it is increasingly being applied 
as a diagnostic test in children with 
suspected monogenic disorders. 6,  7 
The tangible potential of genomic 
sequencing more broadly in medicine, 
as part of “personalized” or “precision” 
medicine, 8 was foreshadowed in 1990 
by Walter Gilbert, who extrapolated 
from the exponential growth of DNA 
sequencing that all newborns would 
have their genomes sequenced by 
2030 or 2040. The idea that genomic 
sequencing will someday become part 
of the standard care of newborns is 
carried forward into today’s dialogue:
As we learn more about effective 
interventions for genetic risk factors, and 
recognize that interventions early in life 
provide significant advantages, it will 
become more and more compelling to 
determine this information at birth.
—F. S. Collins, The Language of Life: DNA 
and the Revolution in Personalized Medicine. 
New York: Harper Perennial (2010)
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Such predictions raise important 
questions: Could genomic sequencing 
become part of the universal 
standard NBS performed by each 
state, replacing conventional 
biochemical testing, or could it be 
offered as an optional supplement? 
How would sequencing be paid for, 
and how would parental informed 
consent be obtained? What impact 
would genomic sequencing in 
newborns have on children’s health? 
What implications would it have 
for issues such as protecting an 
autonomous person’s right not to 
know?
In the diagnostic setting, the goal 
of genome-scale sequencing is to 
identify genetic variants that provide 
a molecular etiology for the patient’s 
symptoms. All other variants are 
considered incidental findings (or 
secondary findings when discovered 
through intentional analysis). 9 These 
additional findings differ widely with 
regard to predictive capacity and 
clinical actionability. Not surprisingly, 
there is disagreement about how 
much genomic information should 
be routinely returned in a pediatric 
setting, 10 – 14 and children and their 
parents are likely to express unique 
preferences. 15,  16 Central challenges 
for clinical implementation thus 
revolve around the boundaries of 
professional responsibility and 
individual or parental choice, best 
practices for informed consent and 
determining parental preferences, 
standards regarding the types of 
findings that should be reported, 
long-term storage of genomic 
information so that it can be acted on 
at the appropriate time, and whether 
and how genomic data should be 
reanalyzed and reinterpreted.
The application of genomic 
sequencing in asymptomatic 
newborns intensifies many of these 
challenges and exposes deep societal 
questions about nonmaleficence, 
beneficence, autonomy, and the 
preservation of each child’s open 
future. 17 – 19 Additionally, the 
economics of such screening must be 
considered before implementation 
on a population level. Although 
the technical features needed for 
rapid genomic sequencing appear 
feasible, interpretation of each 
asymptomatic person’s variant 
profile will remain labor intensive for 
the foreseeable future, and clinically 
useful prediction of future disease 
may prove elusive. Recognizing these 
trends, the Eunice Kennedy Shriver 
National Institute of Child Health 
and Human Development (NICHD), 
National Human Genome Research 
Institute, and the Office of Rare 
Disease Research held a workshop in 
December 2010 to identify elements 
of a trans–National Institutes of 
Health research agenda that could 
inform the possible application of 
new genomic technologies to NBS 
and child health (https:// www. 
nichd. nih. gov/ about/ meetings/ 
2010- retired/ Documents/
Newborn_Research_Agenda.pdf). 
A consensus finding was the need 
to examine the technical, clinical, 
social, and ethical issues related to 
sequencing in the newborn period 
in unison. Subsequently, the NICHD 
and the National Human Genome 
Research Institute issued a funding 
opportunity to develop a consortium 
to explore, in a limited but deliberate 
manner, opportunities to use 
genomic information for broadening 
our understanding of diseases 
identified in the newborn period, 
in the context of public health NBS 
or clinical sequencing of newborns. 
The consortium, called Newborn 
Sequencing in Genomic Medicine and 
Public Health (NSIGHT), is addressing 
3 key research questions:
 • For disorders currently 
screened in newborns, how can 
genomic sequencing replicate 
or augment known NBS results? 
Can sequencing replace current 
screening modalities?
 • What knowledge could genomic 
sequencing provide about 
conditions not currently screened 
for in newborns?
 • What additional clinical 
information could be learned from 
genomic sequencing relevant to the 
clinical care of newborns?
In 2014, 4 groups were funded to 
explore newborn sequencing in 
different clinical contexts by using 
unique study designs ( Table 1 and 
 Fig 1). Each study also included an aim 
examining ethical, legal, and social 
considerations. This article examines 
some of the challenges of newborn 
sequencing in 3 distinct clinical 
settings, describes the 4 projects, 
and puts this research in the context 
of current and future strategies for 
NBS and sequencing of newborns in 
clinical care settings.
CLINICAL SETTINGS FOR NEWBORN 
SEQUENCING RESEARCH: DIAGNOSTIC, 
PREVENTIVE, AND PREDICTIVE
The setting in which genomic 
sequencing is performed affects 
its technical performance, yield, 
and potential benefits and harms. 
In a diagnostic context, newborn 
sequencing is much like any other 
genetic diagnostic modality, 
and the ability to provide a 
molecular diagnosis depends on 
a number of factors including 
genetic architecture, phenotypic 
expressivity, locus heterogeneity 
and the fraction of cases accounted 
for by known disorders, mutational 
spectrum, the types of variants that 
are detectable by sequencing, and 
the quality of the assay performed 
in the patient. In contrast, the 
application of genomic sequencing 
in an asymptomatic newborn 
substantially depends on the power 
of genotype to predict disease 
status in the present or the future. 
Thus, a critical question is whether 
genomic variant data can be used to 
accurately predict disease 
when the pretest probability of 
disease is low, especially in cases 
where there may be no secondary 
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TABLE 1  NSIGHT Project Overviews
BWH, BCH, Baylor College of 
Medicine 
Rady, Children’s Mercy 
Hospital 
UCSF University of North Carolina
Patient cohorts Sick newborns (ICUs). Sick newborns (NICU) Deidentifi ed DBS samples from 
California NBS program
Children affected with known NBS 
fi ndings
Healthy newborns (well 
nursery).
Newborn DBS from consenting 
individuals with primary 
immunodefi ciency
Healthy newborns (prenatal 
recruitment)
Biospecimens Whole blood (newborns) 
and saliva (newborns and 
parents).
Whole blood (parent–infant 
trios)
DBS retrieved from NBS program 
biobank
Cheek swabs
Sequencing Exome sequencing. WGS Exome sequencing Exome sequencing
Illumina Content Exome. Illumina HiSeq 2500, rapid run 
mode
Nimblegen v3 capture Agilent V6.0 capture
Illumina HiSeq. Illumina HiSeq Illumina HiSeq
≥100 × mean coverage. 40–80 × average coverage 40–80 × average coverage
Informatics All newborns: analysis 
of variants in genes 
responsible for childhood-
onset disorders (<18 y).
Clinical features translated 
into phenotype terms and 
differential diagnosis by 
Phenomizer (and custom 
lists)
Metabolic disease NBS samples: 
blinded assessment as an 
initial screen; second-tier 
analysis combining genomic, 
clinical, and MS/MS data
All participants: primary analysis 
blinded to phenotype
Sick newborns/Later-
onset healthy and sick 
newborns: indication-
based analysis of all 
variants in genes relevant 
to the phenotype (if 
applicable).
Immunodefi ciency cohort: 
analysis of genes relevant to 
patient’s phenotype
• Known diagnosis cohort: 
diagnostic or indication-based 
analysis based on phenotypic 
fi ndings
Primary results 
returned
Diagnostic fi ndings (ICU 
patients and others with 
clinical indications).
Diagnostic or likely diagnostic 
fi ndings
No contact or return of results 
for metabolic NBS program 
cohort
Childhood-onset medically 
actionable conditions (all 
participants)
Highly penetrant childhood-
onset or childhood 
treatable conditions (all 
participants).
Offer clinical confi rmatory testing 
to follow up likely pathogenic 
variants for immunodefi ciency 
cohort
Diagnostic fi ndings (affected 
cohort)
Secondary results 
returned
Carrier status for 
childhood-onset 
conditions and selected 
pharmacogenomics (all 
participants).
Incidental genetic disease 
diagnosis if life-threatening 
in childhood
None Parents randomly assigned to 
decision group can select from 
3 categories:
• Childhood-onset non–medically 
actionable conditions
• Carrier status for recessive 
conditions
• Adult-onset medically actionable 
conditions
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gold standard clinical evaluation 
by which to validate the genomic 
prediction.
Sequencing in a NICU population 
of sick infants extends current 
molecular diagnostic strategies to a 
genomic scale, whereas sequencing 
otherwise healthy infants targets the 
prevention of future disease and is 
more akin to current NBS performed 
in a public health setting. Sequence 
information could also be used to 
guide a patient’s care throughout life 
by predicting disease and directing 
management strategies for clinical 
scenarios that emerge, blending the 
predictive, reproductive, diagnostic, 
therapeutic, and prognostic 
value of genomic information. 
The NSIGHT projects differ in the 
clinical scenarios in which the use 
of genome-scale sequencing is 
being studied, spanning the areas 
described below.
Diagnostic Sequencing in the NICU
Level III and IV NICUs care for many 
neonates with genetic disorders, 
including metabolic disorders 20 and 
congenital malformations. 21,  22 
Indeed, genetic disorders and 
congenital anomalies are the 
leading cause of death in the 
NICU. 23 Current approaches for 
diagnosis of suspected genetic 
disorders in NICU patients include 
karyotyping, chromosomal 
microarrays, single-gene testing, 
and gene panels. In many cases, 
the etiologic diagnosis remains 
elusive despite several rounds of 
genetic testing, and clinical genome-
scale sequencing is used for only a 
small fraction of cases. If genomic 
sequencing were used earlier in 
the diagnostic process, it could 
provide more timely definitive 
diagnoses and thereby increase the 
precision of treatments, whether 
therapeutic or palliative, and 
provide answers about prognosis 
and family recurrence risk. In 
addition, sequence data could aid in 
interpretation of the false-positive 
NBS results commonly reported 
in premature infants because of 
their immature organ systems, 
liver enzymatic activity, long-term 
parenteral nutrition requirement, 
and other comorbid conditions.24
Preliminary studies have shown 
potential cost reductions resulting 
from genomic sequencing in neonates 
with genetic disorders. 7,  25,  26 
However, uptake has been 
impeded by concerns about clinical 
interpretation of ambiguous results, 
secondary findings and potential 
parental anxieties, economic factors 
including resistance on the part of 
third-party payers in the absence 
of definitive data on clinical utility 
4
BWH, BCH, Baylor College of 
Medicine 
Rady, Children’s Mercy 
Hospital 
UCSF University of North Carolina
Psychosocial and 
medical outcomes 
research
Surveys of parents and 
physicians assess impact 
of genomic sequencing 
across key domains:
Surveys of parents and 
physicians assess impact of 
genomic sequencing across 
key domains:
Focus groups with: Surveys with parents assess 
decision-making about genomic 
sequencing and its effects on 
individual and dyadic parent 
outcomes:
• Attitudes and preferences. • Attitudes and preferences • Parents of immunodefi ciency 
patients
• Parents’ collaborative decision-
making and confl ict
• Health care utilization. • Health care utilization • Healthy pregnant women • Prenatal anxiety (parents of 
healthy newborns only)
• Health behaviors and 
intentions.
• Health behaviors and 
intentions
• Obstetric and pediatric 
clinicians
• Parental bonding with child
• Decisional satisfaction. • Decisional satisfaction • Attitudes and beliefs about 
genomic sequencing
• Psychological impact. • Psychological impact • Decision confl ict and regret
Psychosocial impact on the 
family.
• Psychosocial impact on the 
family
• Test-related and general distress
Correlation of parents’ 
attitudes about test results 
with their health literacy, 
genomic literacy, anxiety, 
depression, and religiosity
• Beliefs and concerns about the 
child’s future health
Other project aims Although Sanger 
confi rmation is used 
for the main project, 
the study is exploring 
orthogonal sequencing 
by 2 NGS methods as an 
alternative for variant 
confi rmation.
Comparison of rate of 
diagnosis and time to 
diagnosis in WGS and no-
WGS groups
Assess suitability of stored DBS 
as a source of DNA for deep 
sequencing
Semiquantitative metric to 
determine medical actionability
Rates and types of 
actionability measured
Electronic decision aid for 
parental preference setting
TABLE 1  Continued
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 FIGURE 1
A, Diagram of the protocol in progress at BWH and BCH, Boston, Massachusetts. Infants are recruited from the well baby nursery at BWH and from 
the ICUs at BCH and BWH. After a pre-enrollment session with a study genetic counselor and completion of baseline outcomes, enrolled infants are 
randomly assigned to receive NBS and family history or NBS, family history, and exome sequencing. Results are disclosed to the family by a study genetic 
counselor and physician, and postdisclosure outcomes are collected. Follow-up is performed at 3 and 10 months after disclosure. Medical, behavioral, 
and economic outcomes are collected throughout the study from surveys, medical record reviews, and consultation with the families. B, Diagram of 
the protocol in progress at NICUs at Children’s Mercy Hospital, Kansas City (CMH) and Rady Children’s Hospital, San Diego (RCHSD). Eligible patients are 
infants <4 months old in whom a clinical genetic test or genetic consult was ordered, or those with 1 major anomaly or 3 minor structural anomalies, 
or an abnormal laboratory test suggestive of a genetic disease, or an abnormal response to standard therapy for a major underlying condition. Enrolled 
infants are randomly assigned to receive standard diagnostic testing or standard tests and rapid WGS of parent–infant trios. Diagnostic results are 
returned. Primary outcome measures are rate of molecular diagnosis in 28 days, time to diagnosis, and whether the diagnosis provided a change in 
clinical management. C, Diagram of the NBSeq protocol in progress at UCSF. NBSeq uses archived residual DBS from a very large and diverse population to 
examine the diagnostic utility of exome sequencing in 2 parallel projects. For metabolic disorders (left), DBS samples from deidentifi ed true positives (TP), 
false positives (FP), and false negatives (FN) are subjected to exome sequencing, variant calling, and interpretation under blinded models for evaluation of 
fi rst-tier screening and in conjunction with MS/MS and clinical data for evaluation of second-tier screening. A predetermined list of 93 genes relevant to 
the metabolic disorders is the basis for the exome assessment. Consented, identifi ed patients with immune disorders with no gene identifi ed (right) also 
undergo NBS DBS retrieval and exome sequencing and analysis, in this case with a pipeline restricted to immune system genes. Analysis protocols for both 
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and cost-effectiveness, and difficulty 
ordering tests due to institutional 
concerns over high costs. The process 
is also complicated by a need for 
detailed phenotypic information 
for optimal analysis by diagnostic 
laboratories. Provisional genomic 
diagnosis of genetic disease is 
technically feasible in as little as 26 
hours. 27, 28 However, cost is inversely 
related to the turnaround time, 
and the optimal balance of cost and 
clinical utility is unknown. Although 
some aspects of rapid turnaround 
time can be improved through 
technology, limits imposed by variant 
review and clinical interpretation 
standards will remain, including the 
need for communication between 
the clinical team and the laboratory 
for clinical genomic assessment. 
Parental acceptance of testing, given 
the unclear future implications 
for insurability and privacy, is not 
yet known. Finally, the responses 
of neonatologists and parents to 
genomic information warrant more 
study, and rigorous frameworks for 
translating such information into 
precision care plans in NICUs remain 
to be developed.
Preventive Sequencing in a Public 
Health Setting
Current NBS yields few false-
negative results but does incur 
substantial numbers of false 
positives, with attendant emotional 
and financial costs. 29 For example, 
in a study of 176 186 specimens 
screened by MS/MS, there were 51 
true positives, 2 false negatives, 
and 454 false positives that were 
ultimately resolved as nondisease 
after referral to a metabolic center. 30 
Genomic sequencing could function 
as a multiplexed second-tier 
screen, increasing the specificity of 
current MS/MS screening tests by 
distinguishing false-positive results 
from true disease and aiding in the 
differential diagnosis of nonspecific 
biochemical profiles. Sequencing 
could also confirm conditions 
identified through other screening 
methods, 31 –33 aid in providing 
prognosis and appropriate 
treatment, 34 – 37 determine the 
etiology of conditions identified 
through point-of-care testing, 38 and 
provide families with information 
about pathogenic variants that 
could be used for family testing. 
Such analyses could also increase 
knowledge of correlations between 
genotypes and phenotypes and 
might reveal possible genetic 
contributions to false positives, such 
as abnormal MS/MS screening data 
due to carrier status or hypomorphic 
variants. These goals will require 
longitudinal follow-up to obtain 
clinical data and examine genotype–
phenotype correlations to ultimately 
determine the predictive capacity 
and clinical impact of genetic 
variants.
Genomic sequencing could also 
be deployed as a first-tier screen, 
particularly for rare disorders 
that currently lack methods for 
conventional biochemical NBS. 
In the public health context, 
selecting exactly which disorders 
to screen for requires careful 
consideration of factors such as 
age of onset, severity, penetrance, 
treatability, confirmatory testing, 
and opportunities for surveillance. 
Some genetic conditions will fulfill 
the original Wilson and Jungner 
criteria for screening, 39 – 41 but many 
will not. Thus, there is a need for 
scalable methods to determine 
which conditions would be 
appropriate for inclusion in a public 
health screening setting. In addition, 
the current practice of returning 
findings consistent with carrier 
status might be unsustainable given 
that nearly every person is likely 
to be a carrier for a handful of rare 
recessive conditions.
A significant challenge in the 
use of sequencing for NBS is 
the lack of data regarding the 
analytic and clinical performance 
of sequencing as a predictive 
test. Little is known about the 
positive or negative predictive 
value of genomic sequencing 
in asymptomatic people whose 
previous probability of disease is 
very small. Although it may seem 
self-evident that Mendelian diseases 
would be best identified from 
genetic sequence, this assumption 
remains to be demonstrated 
and may not be true. Monogenic 
illnesses are often influenced by 
additional and as-yet-unidentified 
genetic or environmental factors, 
whereas MS/MS measures 
analytes that are typically closer 
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applications undergo refi nement based on integration of observed sensitivity and specifi city with genome analysis tools. Enrollees with immune disorders 
can obtain confi rmational clinical gene testing, and their assessment of risks, benefi ts, and uncertainties of exome sequencing for NBS are solicited. D, 
Diagram of the North Carolina Newborn Exome Sequencing for Universal Screening protocol in progress at the University of North Carolina at Chapel Hill. 
This study is enrolling healthy newborns, identifi ed prenatally, and children affected with known conditions identifi ed through standard NBS (metabolic 
disorders, hearing loss, pulmonary disorders). Parents use an electronic decision aid in addition to an in-person consultation with a genetic counselor to 
determine whether to have their child undergo sequencing. Exome sequencing is performed, with analysis of a panel of genes associated with childhood-
onset medically actionable conditions (NGS-NBS) for all participants and indication-based analysis for patients from the diagnosed cohort. Participants 
are randomly assigned at the time of return of results. Parents in the control arm receive only the primary diagnostic fi ndings and NGS-NBS results, 
whereas parents in the decision arm will use the electronic decision aid to choose between 3 additional categories of optional genomic information 
(adult-onset medically actionable conditions, childhood-onset non–medically actionable conditions, and carrier status for recessive conditions). Parents 
will also participate in longitudinal surveys to assess their responses to the genomic information.
FIGURE 1 Continued
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to relevant phenotypes. Even for 
the best-studied diseases, there 
are substantial challenges in 
interpreting rare variants. Variant 
selection algorithms that maximize 
sensitivity necessarily sacrifice 
specificity, leading to increased 
false-positive results and 
potential downstream harms 
due to unnecessary medical 
interventions. A strategy of 
excluding “variants of uncertain 
significance” (which by definition 
have poor predictive value) from 
genomic screening results may be 
necessary. Historically, the focus 
of NBS on preventable disorders 
has led to low tolerance for false-
negative screening results. With 
genomic sequencing it might be 
necessary to shift the screening 
paradigm from finding all affected 
individuals to finding an optimal 
proportion of cases for a larger 
number of potentially treatable 
conditions.
Predictive Sequencing of Newborns 
in Genomic Medicine
The broadest vision of genomic 
medicine, and potentially the 
most challenging for societal and 
practical reasons, involves the 
use of sequence data to guide a 
patient’s care throughout life. 
Genomic sequencing reveals 
information well beyond the 
scope of conventional NBS. Some 
of this information could result 
in medical action, but most will 
not, raising questions of exactly 
what information should be 
reported and when. 42,  43 Variant 
data could conceivably be held 
for future diagnostic analysis 
in the event that the patient 
develops symptoms of a genetic 
condition. Currently, our ability to 
interpret genetic variants is largely 
confined to simple monogenic 
and oligogenic conditions. As 
we learn to use multifactorial 
models for risk stratification or 
management in a clinically useful 
way, additional information will 
increasingly be available. Within 
this spectrum is the potential 
for genomic information to alert 
clinicians to reconsider the family 
history or interpret physical 
examination findings in a new 
light, and potentially the ability 
to benefit other family members 
before they develop a disease. 
Pharmacogenomic variants could 
guide the real-time selection 
and dosing of medications, 
yielding safer and more effective 
treatments. Recessive carrier 
traits detected in newborns could 
alert parents to genetic risks that 
provide information valuable to 
reproductive planning. Common 
variation for complex conditions 
may motivate families to be more 
vigilant about diet and other 
lifestyle choices. Finally, there is 
the potential for voluntary personal 
exploration of one’s own genomic 
data.
If genomic sequence data are 
available, parents will need to 
make decisions about whether to 
learn about additional categories 
of information that may predict 
future events about their child with 
differing levels of certainty and 
ability to intervene, ranging from 
childhood-onset conditions that 
may not have direct interventions 
or preventive measures, adult-onset 
medically actionable conditions, 
or carrier status for recessive 
disorders. Studies suggest that 
parents are interested in their 
child’s genetic variants, even 
when that information has no 
defined clinical utility, 44 although 
these preferences have largely 
been elicited in hypothetical 
scenarios and may not reflect real-
life choices.
Genomic information may enable 
families to become aware of 
otherwise unsuspected familial risks, 
including potentially actionable 
adult-onset conditions in the 
infant that a parent is unknowingly 
carrying. However, some findings 
may be at odds with professional 
guidance that genetic testing in 
asymptomatic minors should 
generally be done only when 
identification before adulthood 
is needed to prevent harm and 
directly benefit the child. 11,  13,  17 The 
potential to query genome-scale data 
in children for secondary findings 
has elicited vigorous debate over 
the ethical boundaries of return 
of results. The argument has been 
made that benefit to family (eg, 
a parent who is unknowingly at 
risk) may be a valid consideration 
in decisions regarding return of 
results for actionable adult-onset 
conditions in children. 45, 46 Genome-
scale sequencing and analysis in 
newborns would probably require 
modification of current informed 
consent procedures 41,  47 compared 
with a targeted screen focusing on 
a restricted number of conditions. 
If implemented across the entire 
population, genomic sequencing 
would fundamentally alter 
contemporary public health NBS 
procedures, necessitating innovative 
approaches to facilitate parental 
decision-making. Alternatively, 
such testing could be implemented 
through voluntary, out-of-pocket 
testing.
Expanding genomic sequencing 
in newborns to include a broad 
range of conditions demands a 
close partnership between clinical 
providers and parents, similar 
to other areas of medicine in 
which shared decision-making 
is becoming the norm. 48,  49 
Determining criteria for disclosure 
of information will be a challenge 
for clinicians and policymakers 
and will require development 
of decisional supports to help 
parents determine the information 
they want to learn. 50 The clinical 
interactions needed for support of 
parental decision-making would 
move this activity beyond the realm 
of current public health service 
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provision and into the clinical 
domain. Workforce shortages 
may present significant obstacles 
if genome-scale sequencing 
were to become widely available 
in the public health setting, 51 
suggesting that new and more 
scalable materials and procedures 
for communicating the potential 
benefits and risks of learning such 
information would need to be 
developed, validated, and 
deployed. Systems may need to be 
established that enable parents 
to request certain results from 
their child’s genomic information 
over time, allowing them to decide 
iteratively as their values and 
perceptions of risk change or as 
their child attains an age to assent 
or consent.
The complexities of genomic result 
interpretation currently demand 
trained geneticists and genetic 
counselors to provide guidance and 
follow-up management. As genomic 
medicine becomes more mainstream 
in health care, a broader range of 
health care providers will need to 
interact with genetic information, 
which is likely to be increasingly 
viewed as 1 of many risk factors 
influencing future conditions; 
reports will have to be constructed 
with clarity that makes them useful 
for pediatricians and primary care 
providers. The potential use of this 
type of genomic information over 
time would necessitate development 
of new infrastructure to manage 
reporting, reanalysis, storage, 
and integration with electronic 
health records. Such data could 
be used for iterative phenotyping 
of the individual to define the 
clinical relevance of genetic 
variants. However, thresholds for 
reporting or acting on potentially 
relevant variants would have to 
be calibrated against the possible 
harms of false-positive results or 
overdiagnosis, which would lead to 
unnecessary, dangerous, or costly 
medical treatments. 52 The benefits 
of detecting true positives must 
therefore be balanced against the 
magnitude of harms.
NSIGHT RESEARCH GROUPS, STUDY 
DESIGNS, AND KEY QUESTIONS BEING 
ADDRESSED
Each of the 4 members of the 
NSIGHT Consortium independently 
designed and implemented 
study designs that focus on 
somewhat different populations 
and research questions ( Fig 1 and 
 Table 1).
Genome Sequence-Based 
Screening for Childhood Risk 
and Newborn Illness project 
( Fig 1A), led by Brigham and 
Women’s Hospital (BWH) and 
Boston Children’s Hospital (BCH) 
at Harvard Medical School and 
by Baylor College of Medicine, 
is a randomized controlled trial 
assessing the impact of providing 
genomic sequencing information 
to parents and physicians of 
newborns (clinicaltrials.gov 
identifier NCT02422511). The 
study is enrolling a cohort of 
healthy newborns approached in 
the postpartum period from the 
BWH Well Baby Nursery and a 
cohort of sick newborns from the 
BWH NICU and the ICUs at BCH. 
Within each cohort newborns 
are randomly assigned to either 
the control arm (conventional 
NBS results and a detailed family 
history) or the experimental 
arm (genomic sequencing in 
addition to conventional NBS and 
a detailed family history). Parents 
and physicians are surveyed to 
assess the impact of the genomic 
information across several key 
domains including attitudes and 
preferences, health care utilization, 
health behaviors and intentions, 
decisional satisfaction, and 
psychosocial impact on the 
family. 53
The Clinical and Social Implications 
of 2-Day Genome Results in 
Acutely III Newborns project, led 
by Rady Children’s Institute for 
Genomic Medicine and Children’s 
Mercy Hospital, studies the use of 
rapid whole genome sequencing 
(WGS) at 2 large level-IV NICUs 
(∼1000 admissions per year) 
in children’s hospitals ( Fig 1B). 
WGS was adapted for diagnosis 
of rare genetic diseases in NICUs, 
including shortening the minimum 
time to provisional diagnosis to 
26 hours, increasing the analytic 
sensitivity and specificity of 
variant detection to >99.5%, 
and gaining US Food and Drug 
Administration approval to report 
a provisional diagnosis verbally to 
an attending neonatologist if death 
was imminent and the diagnosis 
would inform implementation of 
a treatment that could change the 
outcome. 27,  28 The current study is a 
prospective, randomized controlled 
trial of the diagnostic utility, cost-
effectiveness, and psychosocial 
implications of rapid WGS at the 2 
NICUs (clinicaltrials.gov identifier 
NCT02225522). As part of this 
study, doctors and parents are 
surveyed about their perceptions 
of the risks and benefits of rapidly 
obtaining WGS results.
The goal of the Sequencing of 
Newborn Blood Spot DNA to 
Improve and Expand Newborn 
Screening (NBSeq) project, led by 
the University of California, San 
Francisco (UCSF) and collaborating 
institutions, is to evaluate the 
potential application of exome 
sequencing to public health NBS 
by using dried blood spots (DBS) 
( Fig 1C). The project explores the 
feasibility of exome sequencing to 
augment or replace current 
MS/MS technologies in NBS. Exome 
sequencing is performed at UCSF 
on deidentified archival DBS from 
all California newborns found to 
have metabolic disorders in the 
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past decade, as well as samples 
that were false positives on the 
MS/MS screening. Sequence data 
from newborn DBS 54 are also being 
interrogated in a cohort of 50 
patients who have been clinically 
diagnosed with immunodeficiency 
disorders to determine whether 
sequencing DBS as part of NBS 
could facilitate early diagnosis 
and optimal management of non–
severe combined immunodeficiency 
immune defects. Stakeholder views, 
perspectives, and value preferences 
about the potential expansion of 
NBS are being evaluated through 
focus groups. 55 In addition, legal and 
constitutional issues surrounding 
the potential use of genome-
scale analysis in NBS are being 
examined. 56
The North Carolina Newborn Exome 
Sequencing for Universal Screening 
study at the University of North 
Carolina at Chapel Hill evaluates 
exome sequencing from saliva 
samples in 2 groups: children and 
infants affected with conditions 
identified through standard NBS 
and a cohort of healthy newborns 
whose parents are approached 
for participation prenatally ( Fig 
1D). Parents will use an electronic 
decision aid to assist in decisions 
about exome sequencing. 57 After 
providing informed consent at an 
in-person study visit, those who 
accept sequencing will receive 
results from a “next-generation 
sequencing newborn screening 
(NGS-NBS)” panel of genes 
implicated in childhood-onset 
medically actionable conditions. 58 
Parents will also be enrolled in 
a randomized trial of decision-
making regarding whether to 
learn about 3 types of additional 
genomic findings in their child 
by using the electronic decision 
aid (clinicaltrials.gov identifier 
NCT02826694). The study seeks to 
understand how parents think about 
and consider different categories of 
information, 59 and, combined with 
longitudinal quantitative surveys, 
the study will reveal the spectrum 
of results parents decide to learn, 
issues surrounding returning 
these findings, and consequences 
of decision-making and results 
disclosure.
CROSS-CUTTING CONSORTIUM 
ACTIVITIES
Although the research projects 
address distinct research questions 
and have unique study designs, 
the 4 NSIGHT groups participate 
in consortium activities that build 
on the strengths at each site and 
harmonize data collection to 
improve cross-cutting analysis 
( Table 2). An ethical, legal, and 
social implications workgroup 
brings together the perspectives 
of each project regarding the 
responses of clinicians, families, 
payers, and other stakeholders; 
parental informed consent and 
decision-making; and implications 
for public health NBS programs. 19,  60 
The Common Data Elements 
workgroup is charged with creating 
a common set of data elements 
collected across the 4 research 
groups to enable data sharing 
and combined data analysis. The 
Outcomes and Measures workgroup 
examines the standardized 
instruments being used by each 
group to assess stakeholder 
responses to newborn sequencing 
to facilitate cross-consortium 
analyses. The NSIGHT Consortium is 
working closely with the Newborn 
Screening Translational Research 
Network (NBSTRN) Coordinating 
Center, housed at the American 
College of Medical Genetics 
and Genomics. The NBSTRN, 
created as part of the NICHD’s 
Hunter Kelly Newborn Screening 
Research Program to create a 
shared research infrastructure 
to support NBS researchers, 
provides a mechanism to increase 
understanding of conditions that 
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TABLE 2  Cross-Consortium Working Groups
Ethical, Legal, Economic, and 
Social Issues
Common Data Elements Outcomes and Measure
Key questions Key questions Key questions
• Differences in perceptions 
of benefi ts and risks of 
sequencing between 
symptomatic and 
asymptomatic populations
• Identify common data elements 
in the NSIGHT projects to 
be collected systematically 
across the consortium
• Identify common outcome 
measures in the NSIGHT 
projects to be collected 
systematically across the 
consortium
• Parent willingness to accept 
sequencing and factors 
associated with parents’ 
decisions
• Collaboration with NBSTRN to 
use LPDR for individual cohort 
and combined cohort analysis 
where applicable
• Considerations of the overall 
cost/benefi t ratio of newborn 
sequencing
• Extent to which parents are 
willing to accept uncertainties 
inherent in test interpretation
• Defi ne data elements to be 
shared more broadly, in a 
deidentifi ed fashion, with 
other researchers in the 
NBSTRN
• How key stakeholders make 
decisions about whom to test, 
how to share results, under 
what circumstances, and with 
what goals
• Public policy regarding use 
of genome sequencing as 
part of mandated screening 
programs
LPDR, Longitudinal Pediatric Data Resource (https:// www. nbstrn. org/ research- tools/ longitudinal- pediatric- data- resource).
 BERG et al 
are currently part of routine NBS 
or may be future candidates for 
screening. The NBSTRN resources, 
tools, and network of experts are 
used in population-based pilots of 
new screening technologies and 
natural history studies of screened 
conditions. NSIGHT Consortium 
investigators also maintain close 
ties with other National Institutes of 
Health–funded consortia including 
the Clinical Sequencing Exploratory 
Research consortium 61 and 
Clinical Genome Resource 
consortium.62
CONCLUSIONS
Data gathered from the projects 
in the NSIGHT Consortium 
will address technical, clinical, 
and ethical questions that 
are fundamental to the future 
consideration of sequencing 
in newborns. The projects will 
determine the feasibility and 
utility of this technology in critical 
care and public health settings. 
Design and implementation of 
rapid high-throughput methods 
will be essential to maximize 
the benefit of sequencing for 
certain conditions in the neonatal 
population. Longitudinal follow-up 
of parents will allow the study 
of parental decision-making, 
measure parental preferences in 
real-world settings, and assess 
test-related stress or anxiety. 
Medical outcomes of the children 
who undergo sequencing will need 
to be monitored over many years. 
Ultimately, these data will aid in 
the development of best clinical 
practices and provide guidance on 
the implementation of sequencing 
in newborns. Although genomic 
sequencing will expand our ability 
to diagnose conditions and offer 
personalized treatments, health 
care providers and public health 
entities must be good stewards of 
this technology, ensuring careful 
attention to ethical standards 
and evidence-based outcomes in 
making recommendations about its 
use.
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